BENEFIT-RISK INTEGRATION AND REPRESENTATION

PRESENTATIONS   

• Ashby et al, Benefit Risk analysis of using formal BR approaches for decision making in drug regulation; President’s Invited Lecture, ISCB-33, 22 August 

• Ashby D,  Benefit-risk assessment and communication, A case study of natalizumab, ICPE Montreal, 26-29 August, 2013

• Ashby D.- Benefit-Risk Integration and Representation, CHMP ORGAM, 09th June 2011

• Ashby D.- Current methodological approaches to risk-benefit decision making, DIA EuroMeeting, Geneva, 28-30 March 2011

• Ashby D, Future directions of benefit-risk assessment in Europe, ISPE Mid-Year Meeting, Munich 11-12 April, 2013

• Ashby D.- What role should risk benefit decision making play in the regulation of medicines, Conference on Applied Statistics, Ireland, 16-18 May 2012

• Dierig Ch, Nixon R, A Case Study using the BRAT framework for Benefit Risk Assessment, Basler Biometric Section, 25 September 2012

  http://www.ceb-institute.org/bbs/?p=447

• Hockley K.- Patient and Public Involvement in Regulatory Decision Making, Medical Research Council Phd Student Symposium, 01 May 2012       

• Juhaeri J, Benefit-Risk integration and representation: EU PROTECT, DIA China Meeting, 15 May 2013

• Juaheri J. PrOACT URL and BRAT frameworks Rimonabant case study example, ICPE Aug 2013

• Micaleff A.- The PROTECT Consortium, CIRS Annual meeting Washington: Visualising Benefit-Risk, 16-17 June 2011  
                                                                                                                                                           
• Nixon R.-  Benefit Risk Analysis: Experience in using the BRAT framework, PSI Annual Conference, Birmingham, 15 May 2012                                                                                                                        

• Shahrul Mt-Isa, Formal Benefit Risk Approaches in regulatory decision making of medicinal products, 16th Joint Swiss Symposium on Pharmaceutical Medicine, Berne, 28 November

• Shahrul Mt-Isa, Emerging methods in benefit-risk assessment and decision-making for medicinal products, European statistical Forum, 19 November, Berlin 2012

• Van den Ham et al.- The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation, 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 23-26 Aug 2012, Barcelona 
                   

• Van Staa et al.- Methods for harm-benefit modelling; 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 23-26 Aug 2012, Barcelona            

   

Back to Results